Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events

Zhaoliang Huang, Baiyong Li(China National Pharmaceutical Group Corporation (China)), Tailong Qu, Xinghua Pang, Na Chen, Michelle Xia(Inova Health System), Ma Shun, Max Wang, Tingting Zhong(Guangzhou Development Zone Hospital), Dennis Xia, Xinrong He(Sun Yat-sen University)
Frontiers in Immunology
June 27, 2022
Cited by 42


Related Papers